CO7010835A2 - Novedosas dihidropirimidinoisoquinolinonas y composiciones farmaceuticas de las mismas para el tratamiento de trastornos inflamatorios - Google Patents
Novedosas dihidropirimidinoisoquinolinonas y composiciones farmaceuticas de las mismas para el tratamiento de trastornos inflamatoriosInfo
- Publication number
- CO7010835A2 CO7010835A2 CO14158655A CO14158655A CO7010835A2 CO 7010835 A2 CO7010835 A2 CO 7010835A2 CO 14158655 A CO14158655 A CO 14158655A CO 14158655 A CO14158655 A CO 14158655A CO 7010835 A2 CO7010835 A2 CO 7010835A2
- Authority
- CO
- Colombia
- Prior art keywords
- diseases
- pharmaceutical compositions
- treatment
- formula
- methods
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 208000027866 inflammatory disease Diseases 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 5
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 abstract 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 230000004968 inflammatory condition Effects 0.000 abstract 2
- 208000036971 interstitial lung disease 2 Diseases 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 abstract 1
- 208000035473 Communicable disease Diseases 0.000 abstract 1
- 108091006027 G proteins Proteins 0.000 abstract 1
- 102100033864 G-protein coupled receptor 84 Human genes 0.000 abstract 1
- 102000030782 GTP binding Human genes 0.000 abstract 1
- 108091000058 GTP-Binding Proteins 0.000 abstract 1
- 101001069589 Homo sapiens G-protein coupled receptor 84 Proteins 0.000 abstract 1
- 208000029523 Interstitial Lung disease Diseases 0.000 abstract 1
- 208000019693 Lung disease Diseases 0.000 abstract 1
- 206010047115 Vasculitis Diseases 0.000 abstract 1
- 230000003915 cell function Effects 0.000 abstract 1
- 230000002124 endocrine Effects 0.000 abstract 1
- 210000002865 immune cell Anatomy 0.000 abstract 1
- 230000001771 impaired effect Effects 0.000 abstract 1
- 230000002503 metabolic effect Effects 0.000 abstract 1
- 230000002314 neuroinflammatory effect Effects 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 102000005962 receptors Human genes 0.000 abstract 1
- 108020003175 receptors Proteins 0.000 abstract 1
- 206010039073 rheumatoid arthritis Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Neurosurgery (AREA)
- Urology & Nephrology (AREA)
- Transplantation (AREA)
- Obesity (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Vascular Medicine (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161578979P | 2011-12-22 | 2011-12-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO7010835A2 true CO7010835A2 (es) | 2014-07-31 |
Family
ID=47520068
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO14158655A CO7010835A2 (es) | 2011-12-22 | 2014-07-22 | Novedosas dihidropirimidinoisoquinolinonas y composiciones farmaceuticas de las mismas para el tratamiento de trastornos inflamatorios |
Country Status (34)
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2794627B1 (en) | 2011-12-22 | 2018-09-26 | Alios Biopharma, Inc. | Substituted nucleosides, nucleotides and analogs thereof |
| AR089284A1 (es) | 2011-12-22 | 2014-08-13 | Galapagos Nv | Dihidropirimidinoisoquinolinonas y composiciones farmaceuticas de las mismas para el tratamiento de trastornos inflamatorios |
| USRE48171E1 (en) | 2012-03-21 | 2020-08-25 | Janssen Biopharma, Inc. | Substituted nucleosides, nucleotides and analogs thereof |
| US9441007B2 (en) | 2012-03-21 | 2016-09-13 | Alios Biopharma, Inc. | Substituted nucleosides, nucleotides and analogs thereof |
| EP2935262B1 (en) | 2012-12-20 | 2017-03-15 | Galapagos NV | Novel dihydropyrimidinoisoquinolinones and pharmaceutical compositions thereof for the treatment of inflammatory disorders (gpr84 antagonists) |
| GB201319677D0 (en) * | 2013-11-07 | 2013-12-25 | Eth Z Rich | Cyclopropanation |
| GB201411241D0 (en) * | 2014-06-25 | 2014-08-06 | Galapagos Nv | Novel dihydropyridoisoquinolinones and pharmaceutical compositions thereof for the treatment of inflammatory disorders |
| GB201506894D0 (en) * | 2015-04-23 | 2015-06-10 | Galapagos Nv | Novel dihydropyridoisoquinolinones and pharmaceutical compositions thereof for the treatment of inflammatory disorders |
| JP6918957B2 (ja) * | 2017-03-06 | 2021-08-11 | 上海 インスティテュート オブ マテリア メディカ、チャイニーズ アカデミー オブ サイエンシーズＳｈａｎｇｈａｉ Ｉｎｓｔｉｔｕｔｅ Ｏｆ Ｍａｔｅｒｉａ Ｍｅｄｉｃａ， Ｃｈｉｎｅｓｅ Ａｃａｄｅｍｙ Ｏｆ Ｓｃｉｅｎｃｅｓ | Ｇｐｒ８４受容体拮抗剤およびその使用 |
| EP3403649A1 (en) | 2017-05-16 | 2018-11-21 | Bayer Pharma Aktiengesellschaft | Inhibitors and antagonists of gpr84 for the treatment of endometriosis |
| WO2019096944A1 (en) | 2017-11-15 | 2019-05-23 | Galapagos Nv | Compounds and pharmaceutical compositions thereof for use in the treatment of fibrotic diseases |
| JOP20220156A1 (ar) | 2019-12-19 | 2023-01-30 | Bayer Ag | مشتقات فوروإندازول |
| WO2021123394A1 (en) | 2019-12-20 | 2021-06-24 | University Of Copenhagen | G protein-coupled receptor modulators and a pharmaceutical composition |
| JP2023553295A (ja) | 2020-11-24 | 2023-12-21 | ガラパゴス・ナムローゼ・フェンノートシャップ | 線維性疾患の治療における使用のための化合物及び線維性疾患の治療方法 |
| CA3206499A1 (en) | 2021-02-02 | 2022-08-11 | Liminal Biosciences Limited | Gpr84 antagonists and uses thereof |
| WO2022179940A1 (en) | 2021-02-23 | 2022-09-01 | Bayer Aktiengesellschaft | Furoindazole derivatives as gpr84 antagonists |
| CN115109072A (zh) * | 2021-03-18 | 2022-09-27 | 武汉人福创新药物研发中心有限公司 | 一种gpr84拮抗剂及其制备方法和用途 |
| WO2022218372A1 (zh) * | 2021-04-14 | 2022-10-20 | 武汉人福创新药物研发中心有限公司 | 一种二氢嘧啶并异喹啉酮类衍生物及用途 |
| CA3218018A1 (en) | 2021-04-29 | 2022-11-03 | Bayer Aktiengesellschaft | Furoindazole derivatives as antagonists or inhibitors of gpr84 |
| US20250066335A1 (en) | 2021-06-18 | 2025-02-27 | University Of Copenhagen | Polysubstituted 4-hydroxypyridine and 4-hydroxyquinoline derivatives as gpr84 antagonists |
| EP4361151A4 (en) | 2021-06-21 | 2025-06-11 | Wuhan Humanwell Innovative Drug Research and Development Center Limited Company | Tricyclic compound as a GPR84 antagonist |
| CN115611944A (zh) | 2021-07-15 | 2023-01-17 | 中国科学院上海药物研究所 | 不对称gpr84拮抗剂及其用途 |
| WO2023076668A1 (en) * | 2021-10-29 | 2023-05-04 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Compositions and methods for treatment of cancer |
| GB202202297D0 (en) | 2022-02-21 | 2022-04-06 | Verona Pharma Plc | Formulation production process |
| WO2024083705A1 (en) | 2022-10-18 | 2024-04-25 | Bayer Aktiengesellschaft | Furoindazole derivatives for the treatment of pain |
| CN120569392A (zh) * | 2022-12-30 | 2025-08-29 | 广州市联瑞制药有限公司 | 三环类化合物及其制备方法和应用 |
| WO2024220480A2 (en) * | 2023-04-17 | 2024-10-24 | The Board Of Trustees Of The Leland Stanford Junior University | Method for detecting innate immune action in vivo using gpr84-pet |
| US12194045B1 (en) | 2023-06-26 | 2025-01-14 | Verona Pharma Plc | Particulate composition |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2720085A1 (de) | 1977-05-05 | 1978-11-16 | Hoechst Ag | Pyrimido(6,1-a)isochinolin-2-on- derivate |
| ATE311884T1 (de) * | 1997-07-12 | 2005-12-15 | Cancer Rec Tech Ltd | Cyclin-abhängige-kinase inhibierende purinderivate |
| EP1165556A1 (en) * | 1999-03-31 | 2002-01-02 | Vernalis Limited | Derivatives of pyrimido[6,1-a]isoquinolin-4-one |
| WO2005007092A2 (en) * | 2003-07-08 | 2005-01-27 | Smithkline Beecham Corporation | Novel chemical compounds |
| WO2005050225A2 (en) | 2003-10-31 | 2005-06-02 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 84 (gpr84) |
| WO2007027661A2 (en) | 2005-09-02 | 2007-03-08 | Arena Pharmaceuticals, Inc. | Human g protein-coupled receptor and modulators thereof for the treatment of atherosclerosis and atherosclerotic disease and for the treatment of conditions related to mcp-1 expression |
| US7989461B2 (en) | 2005-12-23 | 2011-08-02 | Amgen Inc. | Substituted quinazolinamine compounds for the treatment of cancer |
| US8217177B2 (en) * | 2006-07-14 | 2012-07-10 | Amgen Inc. | Fused heterocyclic derivatives and methods of use |
| KR20110046514A (ko) | 2008-07-31 | 2011-05-04 | 제넨테크, 인크. | 피리미딘 화합물, 조성물 및 사용 방법 |
| JP2011088847A (ja) * | 2009-10-21 | 2011-05-06 | Takeda Chem Ind Ltd | 三環性化合物およびその用途 |
| CA2860192C (en) | 2011-12-22 | 2020-10-27 | Connexios Life Sciences Pvt. Ltd. | Derivatives of aza adamantane and uses thereof |
| CA2859764C (en) | 2011-12-22 | 2019-12-31 | Novartis Ag | Dihydro-benzo-oxazine and dihydro-pyrido-oxazine derivatives |
| KR102083040B1 (ko) | 2011-12-22 | 2020-02-28 | 커넥시오스 라이프 사이언시즈 피브이티. 리미티드 | 11-베타-하이드록시스테로이드 탈수소효소의 저해제로서 사이클릭 아마이드 유도체 및 이의 용도 |
| AR089284A1 (es) | 2011-12-22 | 2014-08-13 | Galapagos Nv | Dihidropirimidinoisoquinolinonas y composiciones farmaceuticas de las mismas para el tratamiento de trastornos inflamatorios |
| EP2935262B1 (en) | 2012-12-20 | 2017-03-15 | Galapagos NV | Novel dihydropyrimidinoisoquinolinones and pharmaceutical compositions thereof for the treatment of inflammatory disorders (gpr84 antagonists) |
-
2012
- 2012-12-17 AR ARP120104774A patent/AR089284A1/es active IP Right Grant
- 2012-12-20 ES ES17184834T patent/ES2911449T3/es active Active
- 2012-12-20 PT PT171848344T patent/PT3378862T/pt unknown
- 2012-12-20 CA CA2859578A patent/CA2859578C/en active Active
- 2012-12-20 UA UAA201408294A patent/UA111767C2/uk unknown
- 2012-12-20 US US13/721,788 patent/US8927543B2/en active Active
- 2012-12-20 IN IN1033MUN2014 patent/IN2014MN01033A/en unknown
- 2012-12-20 TW TW101148765A patent/TWI567073B/zh not_active IP Right Cessation
- 2012-12-20 HR HRP20220456TT patent/HRP20220456T1/hr unknown
- 2012-12-20 SI SI201231991T patent/SI3378862T1/sl unknown
- 2012-12-20 PE PE2014000988A patent/PE20141685A1/es active IP Right Grant
- 2012-12-20 SG SG11201403169PA patent/SG11201403169PA/en unknown
- 2012-12-20 PL PL17184834T patent/PL3378862T3/pl unknown
- 2012-12-20 JP JP2014547997A patent/JP6062453B2/ja not_active Expired - Fee Related
- 2012-12-20 DK DK12812237.1T patent/DK2794604T3/da active
- 2012-12-20 MX MX2014007363A patent/MX351681B/es active IP Right Grant
- 2012-12-20 WO PCT/EP2012/076275 patent/WO2013092791A1/en not_active Ceased
- 2012-12-20 HU HUE12812237A patent/HUE12812237T4/hu unknown
- 2012-12-20 LT LTEP12812237.1T patent/LT2794604T/lt unknown
- 2012-12-20 PT PT128122371T patent/PT2794604T/pt unknown
- 2012-12-20 KR KR1020147020306A patent/KR102012268B1/ko not_active Expired - Fee Related
- 2012-12-20 EA EA201491245A patent/EA023826B1/ru not_active IP Right Cessation
- 2012-12-20 DK DK17184834.4T patent/DK3378862T3/da active
- 2012-12-20 EP EP12812237.1A patent/EP2794604B1/en active Active
- 2012-12-20 ES ES12812237.1T patent/ES2643379T3/es active Active
- 2012-12-20 CN CN201280061536.3A patent/CN103998448B/zh not_active Expired - Fee Related
- 2012-12-20 BR BR112014015142-3A patent/BR112014015142B1/pt not_active IP Right Cessation
- 2012-12-20 LT LTEP17184834.4T patent/LT3378862T/lt unknown
- 2012-12-20 AU AU2012357067A patent/AU2012357067B2/en not_active Ceased
- 2012-12-20 HR HRP20171404TT patent/HRP20171404T1/hr unknown
- 2012-12-20 EP EP22155038.7A patent/EP4019519A1/en not_active Withdrawn
- 2012-12-20 PL PL12812237T patent/PL2794604T3/pl unknown
- 2012-12-20 SI SI201231087T patent/SI2794604T1/sl unknown
- 2012-12-20 EP EP17184834.4A patent/EP3378862B1/en active Active
- 2012-12-21 UY UY0001034545A patent/UY34545A/es unknown
-
2014
- 2014-01-06 US US14/148,057 patent/US9255095B2/en active Active
- 2014-05-26 PH PH12014501178A patent/PH12014501178B1/en unknown
- 2014-06-18 IL IL233212A patent/IL233212B/en active IP Right Grant
- 2014-06-19 NI NI201400060A patent/NI201400060A/es unknown
- 2014-06-20 CL CL2014001664A patent/CL2014001664A1/es unknown
- 2014-06-23 ZA ZA2014/04607A patent/ZA201404607B/en unknown
- 2014-06-24 CR CR20140305A patent/CR20140305A/es unknown
- 2014-07-22 CO CO14158655A patent/CO7010835A2/es unknown
-
2015
- 2015-12-11 US US14/966,879 patent/US10047083B2/en active Active
-
2017
- 2017-10-11 CY CY20171101053T patent/CY1119434T1/el unknown
-
2018
- 2018-02-18 IL IL257581A patent/IL257581A/en unknown
- 2018-05-04 US US15/971,245 patent/US11220499B2/en active Active
-
2021
- 2021-11-12 US US17/454,712 patent/US20220227751A1/en not_active Abandoned
-
2022
- 2022-04-18 CY CY20221100292T patent/CY1125167T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO7010835A2 (es) | Novedosas dihidropirimidinoisoquinolinonas y composiciones farmaceuticas de las mismas para el tratamiento de trastornos inflamatorios | |
| AR126555A2 (es) | Anticuerpos de oncostatina m humana y métodos de uso | |
| AR124240A2 (es) | Un anticuerpo biespecífico anti-vegf / anti-ang-2, ácido nucleico, vector de expresión, célula huésped y un método de preparación del anticuerpo | |
| AR083785A1 (es) | Anticuerpos humanos contra el ligando 1a de tipo tnf (factor de necrosis tumoral) humano (tl1a) | |
| MX2013011257A (es) | Proceso para la preparacion de dronedarona por n-butilacion. | |
| UA115540C2 (uk) | Антитіло до il-36r | |
| BR112017022008A2 (pt) | composições de di-hidropiridoisoquinolinonas e composições farmacêuticas das mesmas para o tratamento de transtornos inflamatórios | |
| CO2017005950A2 (es) | Productos farmacéuticos y composiciones líquidas estables de anticuerpos contra il-17 | |
| PE20191548A1 (es) | Anticuerpos contra triptasa, composiciones de estos y usos de estos | |
| EA201492285A1 (ru) | Соединения n-алкилтриазола в качестве антагонистов лизофосфатидной кислоты (lpar) | |
| EA201390969A1 (ru) | Модуляторы глюкагонового рецептора | |
| IN2014MN01839A (enExample) | ||
| EA201391371A1 (ru) | Фармацевтическая композиция ситаглиптина | |
| PH12019502853A1 (en) | Novel compounds and pharmaceutical compositions thereof for the treatment of fibrosis | |
| PH12018501849A1 (en) | Novel compounds and pharmaceutical compositions thereof for the treatment of fibrosis | |
| EA201301181A1 (ru) | Триазолопиридины | |
| MX2013007559A (es) | Composicion farmaceutica de complejo de anticuerpo anti-digoxigenina y digoxigenina que se conjuga a un peptido. | |
| EA201491206A1 (ru) | Ингаляционное лекарственное средство, содержащее тиотропий | |
| IT201700081449A1 (it) | Procedimento di purificazione dell'acido ialuronico | |
| WO2012009631A8 (en) | Humanized antibodies targeting the ec1 domain of cadherin-11 and related compositions and methods | |
| WO2012047732A3 (en) | Antibody compositions and methods of use | |
| AR087168A1 (es) | Compuesto derivado de pirimidina sulfonamida | |
| CU24103B1 (es) | Compuestos derivados amido espirocíclicos y sales farmacéuticamente aceptable de los mismos | |
| ECSP12012202A (es) | Anticuerpos il-25 humanizados | |
| MX2014006433A (es) | Nuevos 2h-indazoles como antagonistas del receptor ep2. |